Reviewer's report

**Title:** EARLY Treatment with Azilsartan Compared to ACE-Inhibitors in Anti-Hypertensive Therapy - Rationale and Design of the EARLY Hypertension Registry

**Version:** 1 **Date:** 26 May 2013

**Reviewer:** Giuseppe Derosa

**Reviewer's report:**

Authors describe methods and rationale of “Treatment with Azilsartan Compared to ACE-Inhibitors in Anti-Hypertensive Therapy” (EARLY) registry, a prospective, observational, national, multicenter registry with a follow-up of up to 12 months. EARLY has two co-primary objectives: 1) Description of the safety profile of azilsartan and 2) achievement of BP targets based on recent national and international guidelines for patients treated with azilsartan in comparison to those treated with ACE-inhibitors. The study could be of interest when data will be available.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** Yes, but I do not feel adequately qualified to assess the statistics.

**Declaration of competing interests:**

Nothing to declare